Solid Biosciences Inc. Liabilities, Fair Value Adjustment
Solid Biosciences Inc. (SLDB) reported Liabilities, Fair Value Adjustment of -$900.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueAdjustment · last filed 2026-08-06
- Solid Biosciences Inc. liabilities, fair value adjustment for the quarter ending 2026-06-30 was -$900.00K.
- Solid Biosciences Inc. liabilities, fair value adjustment for the quarter ending 2026-03-31 was -$1.70M.
- Solid Biosciences Inc. liabilities, fair value adjustment for the quarter ending 2025-12-31 was -$2.70M.
- Solid Biosciences Inc. liabilities, fair value adjustment for the quarter ending 2025-09-30 was -$900.00K.
- Solid Biosciences Inc. liabilities, fair value adjustment for fiscal 2025 was -$6.10M.
- Solid Biosciences Inc. liabilities, fair value adjustment for fiscal 2024 was -$4.80M.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$900.00K 10-Q · filed 2026-08-06 | -$2.50M 10-Q · filed 2026-08-06 | -$5.30M derived: sum of 3 quarters · filed 2026-08-06 | -$6.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.70M 10-Q · filed 2026-05-12 | -$4.40M derived: sum of 2 quarters · filed 2026-05-12 | -$5.30M derived: sum of 3 quarters · filed 2026-05-12 | -$6.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$3.60M derived: sum of 2 quarters · filed 2026-03-19 | -$4.50M derived: sum of 3 quarters · filed 2026-08-06 | -$6.10M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$900.00K 10-Q · filed 2025-11-03 | -$1.80M derived: sum of 2 quarters · filed 2026-08-06 | -$3.40M 10-Q · filed 2025-11-03 | -$8.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$900.00K 10-Q · filed 2026-08-06 | -$2.60M 10-Q · filed 2026-08-06 | -$7.40M derived: sum of 3 quarters · filed 2026-08-06 | -$7.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.70M 10-Q · filed 2026-05-12 | -$6.50M derived: sum of 2 quarters · filed 2026-05-12 | -$6.50M derived: sum of 3 quarters · filed 2026-05-12 | -$6.50M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$4.80M derived: sum of 2 quarters · filed 2026-03-19 | -$4.80M derived: sum of 3 quarters · filed 2026-03-19 | -$4.80M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |